MORRISVILLE, N.C.--(BUSINESS WIRE)--Worldwide Clinical Trials, Inc. (Worldwide), an award-winning, full-service, midsize, global CRO, announced today that Shaolian Zhou, Ph.D., has joined the company as senior vice president and lab director for Bioanalytical Services. Based at the company’s Austin, Texas, Bioanalytic Laboratory, Dr. Zhou is responsible for the overall operations of the facility. He serves as a scientific and technical advisor for clients and internal teams, overseeing the generation of quality assays, data and reports, as well as compliance with all scientific and technical goals and regulatory requirements.
“With a strong background in analytical chemistry, bioanalytical sciences and clinical trials, Shaolian adds invaluable expertise to our Bioanalytical Services portfolio – especially for emerging pharmaceutical and biotech companies seeking the attention, insight and prioritization that isn’t reciprocated by large, consolidating CROs,” said Peter Benton, president and COO, Worldwide Clinical Trials. “His experience with personalized medicine and innovative therapies further extends our commitment to deliver uncommon expertise from the very onset of their drug development journey.”
Prior to joining Worldwide, Dr. Zhou served as the global head of Small Molecule Bioanalytical Research and Development for Roche Research and Early Development (pRED). He worked with Novartis Institutes for Biomedical Research as site head of Analytical Sciences and Research Investigator of Metabolism and Pharmacokinetics. He also brings over four years of CRO experience working as a method development manager at Covance Laboratories.
Zhou received his Doctor of Philosophy in analytical chemistry from the University of Tennessee in Knoxville, Tennessee, and conducted his post-doctoral research at the University of Utah in Salt Lake City, Utah. Prior to graduate school, he completed his Bachelor of Science degree in chemistry at Nanjing University.
“Throughout my 20 years of experience in the drug development industry, I’ve been fortunate to acquire a combined expertise in both small and large molecule bioanalysis,” said Dr. Zhou. “With that said, I am excited to play a role in Worldwide’s development of strategic methodologies to facilitate the successful development of therapies that could be transformative to patients’ lives.”
For more information on Dr. Zhou and the expanding Worldwide team, visit www.worldwide.com.
About Worldwide Bioanalytical Services
From discovery to post-marketing, Worldwide partners with pharmaceutical and biotech sponsors to develop custom method transfer/optimize and validate existing method, identify liabilities and de-risk regulated assays, or adapt methods to increase efficiency and cost-effectiveness in both non-GLP and GLP/GCP bioanalysis.
Worldwide scientists routinely analyze more than 30,000 samples per month and have demonstrated capability of up to 45,000 samples per month.
With state-of-the-art bioanalytical instrumentation and more than 2,500 validated assays, Worldwide is at the forefront of the industry in the development of bioanalytical methodology.
In addition to its established capability, Worldwide is developing a LC-MS based platform for both small molecule and protein/peptide biomarkers, enabling drug development support for personalized medicine.
About Worldwide Clinical Trials
Worldwide Clinical Trials employs more than 1,600 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia, and Asia. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, we provide world-class, full-service drug development services.
With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, immune-mediated inflammatory disorders (IMID), oncology and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO.
For more information, visit http://www.worldwide.com.